Hot Features
AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well ... AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. The company was incorporated in 1999 and is headquartered in Ibaraki, Japan. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0.3602 | 0.3602 | 0.3602 | 0 | 0 | CS |
| 26 | 0 | 0 | 0.3602 | 0.3602 | 0.3602 | 0 | 0 | CS |
| 52 | 0 | 0 | 0.3602 | 0.3602 | 0.3602 | 0 | 0 | CS |
| 156 | -0.42632 | -54.2033260438 | 0.78652 | 0.78652 | 0.3353 | 1326 | 0.50189543 | CS |
| 260 | -6.1498 | -94.4669738863 | 6.51 | 6.9237 | 0.3353 | 50032 | 6.79034772 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.